Yahoo MoviesBritney Spears posts new video dancing to a song by ex Justin Timberlake
Britney Spears, 39, shared a video on Instagram on Wednesday as she grooved to JAY-Z's "Holy Grail," which features her ex Justin Timberlake, 39.
Britney Spears, 39, shared a video on Instagram on Wednesday as she grooved to JAY-Z's "Holy Grail," which features her ex Justin Timberlake, 39.
Oprah Winfrey unveiled previously unseen footage on Monday from her interview with the Sussexes.
The Embassy of the State of Qatar in the United States in partnership with the Association of Women in International Trade (WIIT), the US-Qatar Business Council (USQBC) and Qatari Businesswomen Association (QBWA) will host a virtual event on March 9 at 9 a.m. ET titled, "Qatari Businesswomen: Shaping the Present. Leading the Future."
A defunct luxury hotel in Cambodia's capital finished conversion into a 500-room coronavirus hospital on Monday, as authorities enforced a new law imposing criminal punishments for violating health rules and infections continued to rise in the Southeast Asian country. The Great Duke Phnom Penh hasn't been in operation for two years, and is now set up to treat virus patients amid a third wave of the pandemic in Cambodia. Prime Minister Hun Sen assigned Gen. Hun Manet, his eldest son and a powerful army chief, to lead the two-day effort to turn the hotel into a temporary hospital.
LONDON — British children returned to school on Monday after a two-month closure, with Prime Minister Boris Johnson saying he aimed to get the country “ moving closer to a sense of normality.” As part of the plan, millions of high school and college students coming back to U.K. classrooms will be tested for the first few weeks. Authorities want to quickly detect and isolate asymptomatic cases in order to avoid sending entire schools home. “We are being cautious in our approach so that we do not undo the progress we have made so far,” Johnson said as he urged people to get vaccinated. High schools and colleges could reopen in phases to allow for testing. The U.K. government has distributed nearly 57 million rapid “lateral flow” test kits to schools across the country, but there are concerns about the accuracy of the tests, which may result in pupils being forced to self-isolate unnecessarily. But Susan Hopkins, a director at Public Health England, told the BBC that evidence from testing over the past eight weeks suggested less than 1 in 1,000 tests resulted in a false positive. Britain has had Europe’s deadliest outbreak, with nearly 125,000 COVID-19 deaths. —- THE VIRUS OUTBREAK: — With huge virus aid package for nation in sight, Democrats debate filibuster changes — From vote to virus, misinformation campaign targets Latinos in US — UK schools reopen widely, backed by frequent virus testing — Russia finds its Sputnik V vaccine in hot demand overseas but questions arise over whether it can produce the millions of vaccine doses ordered — The Cleveland Indians are minus Ramírez, Reyes after they break virus protocol — Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak ___ HERE’S WHAT ELSE IS HAPPENING: BUDAPEST — Hungarians on Monday awoke to a new round of strict lockdown measures aimed at slowing a record-breaking wave of COVID-19 hospitalizations and deaths powered by virus variants. A rapid rise in pandemic indicators since early February prompted Hungary’s government to announce the new restrictions, including closing most stores for two weeks and kindergartens and primary schools until April 7. Most services are also required to cease operations, and the government urged businesses to allow employees to work from home. Grocery stores, pharmacies, gas stations and tobacconists can stay open. Hungary’s high schools have been remote learning since November and its bars, restaurants and gyms have been closed since then as well. Hungarian Prime Minister Viktor Orban has warned that the strain on the country’s hospitals will soon surpass any other period in Hungary since the pandemic began, and that failing to impose harsher restrictions now would result in a “tragedy.” “The next two weeks will be difficult ... but if we want to open by Easter, we’ve got to close down,” Orban said Friday on a Facebook video. The number of patients on ventilators in Hungarian hospitals has more than doubled in the last two weeks, with 806 patients on Monday compared to the previous peak of 674 in early December. Deaths have also risen sharply to nearly 16,000 confirmed deaths overall. ___ LISBON, Portugal -- Portugal is fast approaching its targets for lifting a national COVID-19 lockdown, just weeks after it was the world’s worst-hit country by size of population. Health experts told Portugal’s president and prime minister in a televised meeting Monday that the 14-day rate of new COVID-19 cases per 100,000 people should fall to the goal of 60 by next week. It is currently 141. The country’s so-called “R” number, showing the number of people that one infected person will pass the virus to, stands at 0.74 -- among Europe’s lowest. The number of COVID-19 patients in intensive care had dropped to 240, which is roughly the maximum at which the national health service can cope, and is forecast to fall to 120 by the end of the month. The government on Thursday will unveil a phased plan for lifting the lockdown introduced in mid-January. Most restrictions, such as the closure of stores, restaurants and cafes, are expected to stay until after the Easter break, amid hopes that tourists will be able to return in May. ___ BERLIN — Germany is looking to ramp up the use of the AstraZeneca vaccine after authorities last week gave the green light for it to be administered to people 65 and over. Hundreds of thousands of doses have been gathering dust in recent weeks due to the restrictions on who could get the vaccine and misgivings among some who were eligible. According to the European Center for Disease Prevention and Control, Germany has received 2.1 million doses of the AstraZeneca shot so far but administered just 721,000. Berlin is opening a sixth vaccine centre Monday at the former Tempelhof airport in the centre of the city that will administer only the AstraZeneca vaccine. Germany’s vaccine campaign has lagged behind Britain and the United States. By Sunday, Germany had given out 5.2 million vaccine doses, with 2.5 million people or about 3% of the population fully vaccinated. Finance Minister Olaf Scholz told public broadcaster ZDF that he expects Germany to be able to administer up to 10 million shots a week by the end of the month. ___ ROME __ The Italian health ministry has officially approved using the AstraZeneca coronavirus vaccine for healthy people over age 65, citing limited vaccine supplies and the need to vaccinate people who might be vulnerable to complications. The order was signed Monday. The European Medicines Agency had approved AstraZeneca for all age groups, but some nations like Italy and Germany initially limited it to under 65s due to what they called limited data. Those limitations are one of the reasons why the 27-nation European Union has lagged so far behind Britain and the United States in vaccinating its people. Millions of doses of AstraZeneca have piled up across Europe, waiting to be given out. ___ JERUSALEM — After delays, Israel started vaccinating Palestinians who work inside the country and its West Bank settlements on Monday, more than two months after launching an immunization blitz of its own population. Palestinian labourers who crossed into Israel at several West Bank checkpoints received their first doses of the Moderna vaccine from Magen David Adom paramedics. The vaccination drive orchestrated by COGAT, Israel’s military agency co-ordinating government operations in the West Bank, had been beset by postponements. Some 100,000 Palestinian labourers from the West Bank work in Israel and its settlements, which are widely seen internationally as illegal and an obstacle to peace. Israel has administered over 8.7 million doses of the Pfizer vaccine to its population of 9.3 million. Over 3.7 million Israelis — more than 40% — have received two doses of the vaccine. But until Monday, Israel had provided few vaccines for Palestinians in the West Bank and Gaza Strip, a move that has underscored global disparities and drawn international criticism. ___ COPENHAGEN, Denmark — Norway saw a 19% drop in marriages in 2020 compared to the previous year, which had already seen the lowest figure since 1927. Norway’s statistics agency said Monday that the pandemic and measures to counter it led to the fall. In 2020, 16,200 weddings were performed. On top of that, “the decline of 3,000 marriages from 2019 to 2020 is unparalleled and is the largest decline from one year to another since 1919,” said Ane Margrete Toemmeraas of Statistics Norway. “Figures show that the coronavirus measures from March 12, 2020 caused many to postpone their wedding,” Toemmeraas said. Whether it “leads to an increase in 2021, as many of the postponed weddings may take place this year instead, will become clear later on.” ___ HANOI, Vietnam — Vietnam administered its first COVID-19 doses Monday to the front-line workers who made the nation’s relative success in controlling the pandemic possible — health workers, contact tracers and security forces who handled quarantine duties. The Southeast Asian nation of 96 million people has a goal to inoculate at least half of the population by the end of the year. Thousands of doctors, nurses and technicians working at hospitals designated to treat COVID-19 patients lined up in the morning and received the first jabs of the AstraZeneca vaccine. “I have been waiting for this day for a long time,” nurse Nguyen Thi Huyen said after she got her injection. Huyen has been caring for COVID-19 patients at a tropical disease hospital in Hanoi the past year. Health protocols have limited her time with family, among other challenges. ___ KABUL, Afghanistan — The U.N. children's agency says Afghanistan has received nearly half a million coronavirus vaccine doses via the global COVAX initiative. War-torn Afghanistan received 468,000 AstraZeneca vaccines on Monday, the first shipment through COVAX, UNICEF said in a statement. The vaccines were made by the Serum Institute of India, and arrived in the capital of Kabul aboard an Emirates flight, UNICEF said. More vaccines will arrive in the coming weeks and months. India previously donated 500,000 doses of AstraZeneca vaccines to Afghanistan. ___ COLOMBO, Sri Lanka— Sri Lanka's government has ended a yearlong work-from-home program for public employees due to the pandemic. Employees were ordered to report back to their workplaces starting Monday in order to ensure the uninterrupted delivery of public services, At the start of the pandemic last year, the government imposed a lockdown across the island nation for more than a month, and temporarily closed some government departments. As a precaution, a limited number of employees were allowed to go to work, while in some institutions, employees had been permitted to work from home since last April. ___ WELLINGTON, New Zealand — New Zealand says it will now use only the Pfizer vaccine to inoculate its population against the coronavirus, departing from earlier plans to use four different vaccines. Prime Minister Jacinda Ardern announced the strategy Monday, saying the decision was based on the Pfizer vaccine’s effectiveness. She said this would make it easier and fairer for all New Zealanders to have access to the same vaccine. However, the strategy may also be driven in part by delays in getting vaccines approved. So far, New Zealand’s medical regulators have approved only the Pfizer vaccine and are reviewing two other shots. Ardern said New Zealand has purchased 10 million doses of the Pfizer vaccine, enough to inoculate all 5 million residents with the required two doses each. She said most of the doses are expected to arrive during the second half of this year. New Zealand has so far completed inoculations of only a few thousand people, mainly border workers. The country has stamped out community spread of the virus. ___ SEOUL, South Korea — A South Korean province near the capital of Seoul has ordered local business owners and farmers to have all foreign employees tested for the coronavirus in the next 15 days, targeting tens of thousands of workers. The mass testing campaign is the most significant step South Korean officials have taken yet to stem transmissions among migrant labourers, who often face harsh working and living conditions that health authorities say make them more vulnerable to infections. The order issued Monday by Gyeonggi province Gov. Lee Jae-myung covers at least 85,000 legally hired migrant workers, with fines up to 3 million won ($2,600) for noncompliant employers. The order also requires employees to ensure their undocumented workers get tested too. The province has encouraged these workers to come forward, saying they won’t be reported to immigration authorities if they are tested before March 22. South Korea has confirmed more than 92,000 virus cases, including 1,642 deaths. ___ DETROIT — People who are homeless will be eligible for COVID-19 vaccines in Michigan starting Monday. Health officials say it’s a critical step in curbing infections and making sure vulnerable populations have access. “Our vulnerable populations are high priority for us right now,” Ingham County Health Officer Linda Vail said, according to the Lansing State Journal. “This opens the door to make sure that population is also vaccinated and we don’t continue to have outbreaks in shelters.” The news comes as infection rates are dropping and vaccine campaigns are ramping up. Gov. Gretchen Whitmer recently announced the further loosening of the state’s coronavirus restrictions, easing capacity limits in restaurants and other businesses while also allowing for larger indoor and outdoor gatherings. ___ WASHINGTON — Dr. Anthony Fauci is projecting that U.S. high school students will be able to get vaccinated early in the next school year and that elementary school students should be line for vaccinations in early 2022. Fauci, President Joe Biden’s chief medical officer and director of the National Institutes of Allergy and Infectious Diseases, told CBS News’ “Face the Nation” that vaccines for teens will be available “maybe not the first day but certainly in the early part of the fall.” Currently, three vaccines are approved for use in the United States. The single-shot Johnson & Johnson vaccine and the two-shot Moderna vaccine are approved for individuals 18 and older. Pfizer’s vaccine is approved for 16 and up. Trials are underway to determine the safety of vaccines on younger people. Teenagers contract the coronavirus almost twice as often as younger children, according to the Centers for Disease Control and Prevention data. The Associated Press
The United States said on Monday it is committed to defending Saudi Arabia following drone and missile strikes by Yemen's Iran-aligned Houthi movement, including on a Saudi facility vital to oil exports. Saudi authorities said there were no casualties or property losses from Sunday's attacks targeting an oil storage yard at Ras Tanura, site of a refinery and the world's biggest offshore oil loading facility, and a residential compound in Dhahran used by state-controlled oil giant Saudi Aramco.
MassRoots, Inc. ("MassRoots" or the "Company") (OTC:MSRT), a technology company focused on the regulated cannabis industry, announced today that it has launched a new and improved MassRoots.com focused on monetizing its web traffic.
Abu Dhabi’s Technology Innovation Institute Appoints International Experts to Board of Advisors at Secure Systems Research Centre
Biomarck Pharmaceuticals presents at H.C. Wainwright 2021 Global Life Sciences Conference on March 9-10, 2021
NEW YORK — They're just your regular neighbourhood pharmacists, but some now wear superhero capes. Local pharmacy owners are filling in the gaps as federal, state and county authorities across the country struggle to ramp up vaccinations vital to crushing the COVID-19 pandemic. In some small towns across the U.S., an independent pharmacy is the only local place where residents can get a COVID-19 vaccination. President Joe Biden recently celebrated the injection of the 50 millionth dose of COVID-19 vaccine since his inauguration. But the huge undertaking has been hampered by vaccine shortages and concerns whether marginalized communities are getting access to shots. The hope is that local pharmacies will now play a key role in getting more Americans inoculated. They have become vaccine providers by applying to state health officials and the Federal Retail Pharmacy Program for COVID-19 Vaccination, which has been distributing vaccine to networks of independently owned pharmacies, as well as the big national chains. The Biden administration’s coronavirus co-ordinator, Jeff Zients, said at the start of the program last month about 6,500 pharmacies would receive a total of 1 million doses, with more pharmacies joining the program as vaccine production increases. The program doesn't fully fill the gaps, however — more than 400 rural counties lack a retail pharmacy that’s included in the partnership. Giving vaccinations requires long hours and administrative work, and there’s little or no money in it for pharmacy owners. They don’t have to pay for the COVID-19 vaccine, unlike flu and other vaccines, but they do have administrative costs they may be able to recover when patients have insurance. Still, the money is not their immediate concern. Adam Bayer and his wife have given out shots at their store, Hillcrest Pharmacy in Vernon, Texas. The work can be intense — the first batch of 100 doses took them a day and a half to administer. Besides giving the vaccine, they must monitor patients for 15 minutes for signs of allergic reactions. Bayer applied to become a vaccine provider because he believed he was in a position to help fight the pandemic. He’s been proactive and reaching out to customers. “We’re calling patients who we know aren’t online,” he says. “My prayer is that we’re not leaving people behind.” Good Neighbor Pharmacy, one of the networks whose members are participating in the Federal Retail Pharmacy program, has so far been allotted 75,000 doses for pharmacies in Kansas, Kentucky, Nebraska, Texas and Guam, says Jenni Zilka, a senior vice-president at the network. Those doses began arriving the week of Feb. 11. All told, the Federal Retail Pharmacy program has 21 companies taking part including big drugstore and grocery chains and mass merchandisers like Costco and Walmart. However, not all the big chains like CVS, Rite-Aid and Walgreen's are giving out vaccinations in every state they're located in. The program is giving a boost to the independents that have been losing ground to the nationwide retailers for decades. In 2015, independents accounted for 36% of the 61,000 pharmacies across the U.S., according to the National Community Pharmacists Association, a trade group. By 2019, they accounted for 35% as the number of pharmacies overall grew to 61,480. Pharmacists who get a smile and a nod when customers pick up routine prescriptions are now being greeted by applause and tears from customers, first responders and residents of assisted-living centres in communities across the country. The pharmacists themselves are equally emotional. “The opportunity to call someone who’s 85 and tell them, ‘I’m going to give you a vaccine’ is a pretty profound experience,” says Chris Antypas, co-owner of Asti’s South Hills Pharmacy in Pittsburgh, which has given out several hundred doses. Besides giving COVID-19 shots in their stores, pharmacists have also set up mass immunization clinics. They’re already experienced at giving out shots — for years they’ve administered flu, pneumonia, shingles and other vaccinations. But they’re required to get additional training before they can give out COVID-19 shots: They must learn how to handle and store the vaccine, and unlike with other immunizations, they must report to health officials who gets the vaccines, and the name of each dose’s manufacturer. Matt Hopp owns what’s known as a closed-door pharmacy — it specializes in packaging and delivering medication for assisted-living facilities and nursing homes in the Atlanta area. So far, Guardian Pharmacy has administered 1,500 doses to people in assisted living and who have come to drive-through clinics. Hopp says he’ll bill Medicare and insurance companies later. “We’re more focused on getting the vaccine out there and into arms,” he says. Many pharmacists, especially those running mass clinics, are getting help from their communities. School districts, fire departments, landlords with empty stores have been offering the use of their space, Antypas says. Mayank Amin, who has set up mass clinics in the Philadelphia suburbs, has gotten help from doctors and other health professionals who volunteered to administer shots, sometimes as many as 1,000 over an eight-hour period. Amin, owner of Skippack Pharmacy in Skippack Township, Pennsylvania, has also fielded requests to set up more clinics. “As soon as word spread that we were doing, this, we started getting calls from different counties and mayors,” Amin says. Like other pharmacists, the owners of Ochoa’s Pharmacy had to give Texas health officials detailed information about the population they serve and their physical plant, including how they would store and administer the COVID-19 vaccine. The Ochoa family, which has two pharmacies in the town of Edinburg, even had to tell the state the model number of their refrigerators and how they would log the temperatures the vaccine would be stored at. “When we received the email saying we were going to receive vaccine, we started to cry,” Alessandra Ochoa says. Her family's pharmacies are located in Hidalgo County, an area hard-hit by the virus. Pharmacists have had to contend with the same uncertain pace of vaccine distribution as hospitals and other medical facilities. They fill out surveys that include estimates of the number of doses they need, but they don’t know how many doses they’ll get — or if they’ll get any at all. “You don’t want to get excited and get zero,” Amin says. But when the vaccine does arrive, Amin says he has to be quick on his feet, securing a location for a clinic. But despite the stress of getting a clinic together, Amin manages to bring a little levity to vaccine distribution — he’ll arrive dressed in a superhero costume, complete with red cape. People who get their shots are overwhelmed with gratitude. When Guardian Pharmacy's employees arrive with the vaccine, assisted living residents greet them with applause. And Ochoa has seen many deeply emotional moments. “They’re praying as they’re receiving it — praying the Hail Mary, the Our Father, and there are tears streaming down their faces,” she says. Joyce M. Rosenberg, The Associated Press
Public health experts are warning that Americans may be growing complacent with testing. U.S. death toll reaches 525K. Latest COVID-19 news.
Global power leader Cummins Inc. (NYSE: CMI) and Cummins Westport Inc. announced today that the ISX12N+Endurant HD N powertrain from its Integrated power portfolio is now available for heavy-duty customers, delivering a fully integrated natural gas powertrain. The combination of the ISX12N near zero natural gas engine and the Endurant HD N 12-speed automated transmission from Eaton Cummins Automated Transmission Technologies is well suited for heavy-duty regional haul fleets looking to lower emissions and improve their sustainability profile.
Alliance to Accelerate Development and Commercialization of Next-Gen Aerospace TechnologiesBOCA RATON, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- Xeriant, Inc. (OTC PINK: XERI), a new aerospace technology holding company, announced today that it has signed a letter of intent to form a strategic alliance with Mente Systems Inc. (DBA TheIncLab), an award-winning artificial intelligence (AI) company based in McLean, Virginia, and a leading innovator in the development of AI-enabled systems focused on the human experience, called AI+X. As part of the agreement, Xeriant plans to make a strategic investment in TheIncLab as it expands its operations and array of technology products. Established in 2015, TheIncLab designs and builds rapidly deployable, intelligent systems that optimize the interface between humans, technology, data and the environment, serving Fortune 500 companies in a wide range of industries, including aerospace and defense customers. Among its clients are the U.S. Navy’s Office of Naval Research and Special Operations Command, the Johns Hopkins Applied Physics Laboratory, Samsung, NuVasive and Corning. Xeriant plans to work with TheIncLab to assess and maximize the impact of disruptive aerospace technologies and develop a strategy for accelerating their path to integration and commercialization, including advanced VTOL (vertical takeoff and landing) vehicles, a particular area of focus and expertise shared by both companies. “TheIncLab has an unparalleled record of developing innovative, AI-powered solutions to improve enterprise functions, and having them as a strategic partner will be a critical asset as we move forward and expand our portfolio of acquisitions. We plan on using AI-based modeling as a decision-making support arm to evaluate technologies, product lifecycles, intellectual property, business valuations, sales projections, market size, synergies and risk profiles related to future acquisitions. Their involvement with the aerospace and defense sector brings invaluable insight as we begin to explore AI-based generative design, engineering and prototyping for new aircraft concepts,” commented Keith Duffy, CEO of Xeriant, Inc. TheIncLab is continuing its work on prototyping cockpit concepts and AI-enabled systems for the Future Vertical Lift (FVL) program, a research and development initiative dedicated to the modernization of the U.S. Armed Forces’ vertical lift fleet, initially targeting the replacement of the Black Hawk helicopter by 2035. The goal of FVL is the design and development of next-generation, technologically advanced manned and unmanned VTOL-capable aerial vehicles with improved maneuverability, range, speed, payload, survivability, reliability, and reduced logistical footprint compared with existing military helicopters. “As a strategic partner, Xeriant can achieve cross-pollination of technologies across its many organizations, allowing for stronger cohesion and gains across its network of companies. Our AI experience with evaluating and integrating emerging technologies sets the stage for a valuable and mutually beneficial relationship between TheIncLab and Xeriant. Through our talented multi-disciplinary team, we leverage the power of AI to deliver tangible solutions and business value to our clients,” stated Adriana Avakian, Founder and CEO of TheIncLab. The role of AI in the aerospace industry continues to expand as companies streamline business processes and integrate new and transformative technologies. AI harnesses the power of digitization and data analytics to drive efficiency and innovation, augmenting and extending human capabilities in a range of aerospace applications impacting everything from supply chain management to customer relations. According to a July 2020 report by Grand View Research, the global artificial intelligence market size was valued at USD $39.9 billion in 2019 and is expected to reach USD $733.7 billion by 2027, expanding at a CAGR of 42.2%. PwC estimates that AI will generate over $15 trillion in global GDP gains over the next decade, with half the gains coming from increased worker productivity. About Mente Systems Inc. (TheIncLab) Founded in 2015, TheIncLab is the first human-centered artificial intelligence experience (AIX) lab. TheIncLab's award-winning, multi-disciplinary team is focused on designing and developing AI-enabled systems that learn and collaborate with humans. The company offers its clients comprehensive capabilities for rapid ideation, software development and building of smart systems and hardware solutions. Its open, scalable AI architecture approach, combined with years of experience in interactive engineering and emerging technology innovation, allows for rapid prototyping and deployment of transformational concepts, products and solutions designed to work with meaningful human interaction, effectively bridging the gap between humans and intelligent systems. TheIncLab’s MenteAI product, an open edge framework, allows companies to quickly innovate and build custom interfaces that bridge and augment the interaction of people with AI- enabled systems. Adriana Avakian was recently named to the 2021 Forbes Next1000 List of Upstart Entrepreneurs who are Redefining the American Dream. About Xeriant Xeriant, Inc. (d.b.a. Xeriant Aerospace) is a holding and operating company focused on acquiring, developing, and commercializing revolutionary, eco-friendly technologies with applications in aerospace, including innovative aircraft concepts targeting emerging opportunities within the aviation industry. In 2019, Xeriant acquired a unique, scalable, multi-purpose VTOL aerial platform called Halo, which is protected under a broad utility patent. Xeriant is located at the Research Park at Florida Atlantic University in Boca Raton, Florida adjacent to the Boca Raton Airport. The Company is an OTC Markets public company trading under the stock symbol, XERI. For more information, please go to www.xeriant.com SAFE HARBOR FORWARD-LOOKING STATEMENTS In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Xeriant, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations concerning our ability to attract investors. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. XERIANT, INC. CORPORATE Investor Relations:Matt Chipman(818) 923-5302IR@xeriant.comwww.xeriant.com
Iteris, Inc. (NASDAQ: ITI), the global leader in smart mobility infrastructure management, today announced that its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value.
• Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its fourth quarter and year-end financial results on Monday, March 15th. Corbus management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, who will be joined by additional members of the Corbus management team. Interested participants and investors may access the conference call by dialing (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com and will be archived for 90 days Following the event. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform. Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here. For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Corbus Pharmaceuticals Contacts: Ted Jenkins, Senior Director, Investor Relations and Corporate Communications Phone: +1 (617) 415-7745 Email: ir@corbuspharma.com Lindsey Smith, Director, Investor Relations and Corporate Communications Phone: +1 (617) 415-7749 Email: mediainfo@corbuspharma.com
IGNITE International Brands, Ltd. (CSE:BILZ, OTCQX: BILZF) ("IGNITE" or the "Company"), is pleased to announce today the appointment of Ms. Vered Elkouby Nisim, as an independent, non-executive director, to its board of directors. Ms. Nisim has extensive marketing experience including work with JH Design Group, a US leading manufacturer of licensed products including iconic brands such as the NFL, NBA, MLB, NHL, NASCAR, Marvel, and many more. Ms. Nisim is also the founder of Brellascope, a cutting-edge boutique marketing firm specializing in unique branding strategies and custom marketing solutions. Ms. Nisim has extended her business experience into cannabis as a member of local and state cannabis associations, committees and boards in California and is Founder/Managing Partner, Curagenics, LLC, a company using leading-edge bio-delivery systems to bring the health benefits of CBD to people for pain management, anxiety and several other physical and neurological conditions.
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), to its Board of Directors. “We are very pleased to welcome Lisa to TRACON’s Board of Directors,” said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. “She is a physician who has focused the majority of her career on the commercialization of innovative products, including Gardasil® and Singulair® at Merck, prior to her appointment as Head of the Global Commercial Operations at GSK. Her strong track record of successful strategic, operational and financial management, combined with her vast commercial experience will be invaluable to TRACON as we execute on our plan to complete clinical development and potentially commercialize envafolimab in the United States in 2023.” Dr. Johnson-Pratt brings more than two decades of broad business and commercialization leadership experience to TRACON. Dr. Johnson Pratt currently serves as Sr. Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) which is focused on discovering, developing and commercializing RNA-targeted therapeutics for a broad range of diseases. Dr. Johnson-Pratt joined Ionis following its acquisition of Akcea Therapeutics, where she was an Executive Council Member and led an integrated medical team responsible for the commercialization strategy of two novel late stage antisense assets. Prior to that, Dr. Johnson-Pratt was Head of Global Pharma Commercial Operations at GSK. During her time at GSK, she also served as Head of Early Pipeline Commercial Strategy supporting assets in early-stage development across multiple therapeutic areas, including oncology. From 1996 to 2013, Dr. Johnson-Pratt held clinical development and commercial leadership roles at Merck & Co., Inc. During this time, she led global marketing strategy, country operations and global band management teams. Her career has spanned globally, including time in China and Vietnam, supporting products that have contributed strongly to improving patient health for vulnerable patients. Dr. Johnson-Pratt received her medical degree and completed her residency in Internal Medicine, from Howard University. She completed a Fellowship in Clinical Pharmacology and Pharmaceutical Medicine at Howard University. She holds a Diploma of Pharmaceutical Medicine from the Royal College of Physicians. Dr. Johnson-Pratt is the Founder of Ananias Ventures which supports projects focused on issues related to vulnerable women and children, and is on the board of Young People in Recovery (YPR) a national non-profit that supports young people to thrive after recovering from substance abuse. “TRACON has a first-class management team, an efficient platform to conduct global clinical trials, and a promising drug candidate with near-term commercial potential in envafolimab,” said Dr. Johnson-Pratt. “I am thrilled to support TRACON’s mission to commercialize envafolimab and address significant unmet needs in patients with cancer.” About TRACON TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com. Forward-Looking Statements Statements made in this press release regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding TRACON's and its collaboration partners’ plans to further develop product candidates, expectations regarding the timing and scope of clinical trials and availability of clinical data, expected development, regulatory and commercial milestones and timing thereof, potential utility of product candidates, and TRACON’s business development strategy and goals to enter into additional collaborations. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development and regulatory approval of novel pharmaceutical products; whether TRACON or others will be able to complete or initiate clinical trials on TRACON’s expected timelines, if at all, including due to risks associated with the COVID-19 pandemic; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; the fact that TRACON has limited control over whether or when third party collaborators complete on-going trials or initiate additional trials of TRACON’s product candidates; the fact that TRACON’s collaboration agreements are subject to early termination; whether TRACON will be able to enter into additional collaboration agreements on favorable terms or at all; potential changes in regulatory requirements in the United States and foreign countries; TRACON’s reliance on third parties for the development of its product candidates, including the conduct of its clinical trials and manufacture of its product candidates; whether TRACON will be able to obtain additional financing; and other risks described in TRACON’s filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Company Contact:Investor Contact:Mark WigginsAndrew McDonaldChief Business OfficerLifeSci Advisors LLC(858) 251-3492646-597-6987mwiggins@traconpharma.comAndrew@lifesciadvisors.com
“Is this a dream, I hope it’s not a dream,” Kim said between sobs while accepting the Best Young Actor award.
KEY FINDINGS The global precision medicine market is evaluated to register a CAGR of 9. 86%, during the forecast years of 2021 to 2028. The market growth is mainly accredited to key factors, including, the use of digital collaboration in exchanging useful information to develop precision medicine, the demand for preventive care, the identification and characterization of essential genes within the human genome, and others.New York, March 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL PRECISION MEDICINE MARKET FORECAST 2021-2028" - https://www.reportlinker.com/p06033701/?utm_source=GNW MARKET INSIGHTSPrecision medicine entails a detailed study of patient-specific information, in order to characterize and diagnose diseases. The concept of precision medicine is rapidly augmenting across the medical community through massive expansions in several improved technologies, like bioinformatics, molecular biomarker analysis, next-generation sequencing, and big data analytics, among various others.Precision medicine works on the basis of the drug’s reaction, with the patient’s particular genetic type.Comprehending the drug target reaction also plays an essential role, in terms of discovering precision medicine and drug development.The data generated from gene sequencing forums and clinical research contribute towards understanding drug targets for personalized medicine, as well.In this regard, the information available and accessible through online collaborations can be shared among multiple research groups, thereby assisting in exchanging useful information for developing precision medicine.As a result, the initiative aims in precision medicine encourages and attracts scientists from diverse disciplines.REGIONAL INSIGHTSThe global precision medicine market growth is assessed through the study of Europe, the Asia-Pacific, North America, and the rest of the world.North America is set to harbor the highest market share by 2028, primarily owing to numerous established diagnostics manufacturers’ focus on expanding their portfolio, in terms of NGS-based molecular diagnostics.Moreover, they also collaborate with pharmaceutical giants and service providers to co-market molecular diagnostics solutions, along with complementary precision medicine solutions.COMPETITIVE INSIGHTSMarketing plays an important role in the global precision medicine market, since patients require increased levels of awareness for moving into personalized care. Hence, aligning with this aspect, robust competitive strategies are likely to enable firms to sustain and develop well.Some of the leading companies in the market are, Astra Zeneca PLC, Bio-Rad Laboratories Inc, Abbott Laboratories, Eli Lilly & Company, etc.Our report offerings include:• Explore key findings of the overall market• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions• Market Segmentation cater to a thorough assessment of key segments with their market estimations• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developmentsCompanies mentioned1. ABBOTT LABORATORIES2. ASTRA ZENECA PLC3. BIOCRATES LIFE SCIENCES AG4. BIO-RAD LABORATORIES INC5. DANAHER CORPORATION6. EAGLE GENOMICS LTD7. ELI LILLY & COMPANY8. F. HOFFMANN-LA ROCHE9. INTOMICS10. LABORATORY CORPORATION OF AMERICA HOLDINGS11. NANOSTRING TECHNOLOGIES12. NOVARTIS AG13. PFIZER INC14. QIAGEN NV15. QUEST DIAGNOSTICS INCORPORATEDRead the full report: https://www.reportlinker.com/p06033701/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
The "Ethiopia: Sesame Seed Market" report has been added to ResearchAndMarkets.com's offering.
It's high season for initial public offerings (IPOs) -- with more companies going public than ever before last year, a record number of stocks managing to double within their first day of trading, and signs that 2021 will be another huge year for new market entrants. Many recent IPO stocks have posted gains since going public, but investors still have to be selective and focus on high-quality companies in order to maximize long-term returns and avoid getting caught up in hype. With that in mind, read on for a look at three of the best IPO stocks to buy in March: two that have already gone public, and one that will be making its market debut this month.